Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced Solid Tumors
Status:
Completed
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
This randomized phase I trial studies the side effects and best dose of RO4929097 in treating
patients with advanced solid tumors. RO4929097 may stop the growth of tumor cells by blocking
some of the enzymes needed for cell growth.